SAFI Biotherapeutics Inc.
Cambridge, MA
- UEI
- LQ1FYSTC9L65
- CAGE
- 8JC22
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1 Broadway, Cambridge, MA 02142, USA
- Website
- safi.bio
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Manufacturing process intensification for pluripotent stem cell-derived rare red cell production - project… | National Heart Lung and Blood Institute | $1,136,528 |
About SAFI Biotherapeutics Inc.
SAFI Biotherapeutics Inc. is a pre-clinical blood cell therapy company based in Cambridge, Massachusetts, focused on developing innovative manufacturing processes for human blood cells. Registered in SAM.gov since March 2020, the company specializes in creating cost-efficient and scalable bioprocessing technologies for producing human red blood cells (RBCs) from stem cell sources. As a for-profit corporate entity, SAFI Biotherapeutics has positioned itself at the intersection of biotechnology and medical research, with a primary emphasis on advancing cell manufacturing techniques that can potentially transform therapeutic and diagnostic approaches in hematology.
The company has secured federal grant awards primarily from the National Heart, Lung, and Blood Institute (NHLBI), focusing on advanced blood cell production technologies. Its most recent significant award is a $568,264 project grant (R41HL178144) aimed at developing a scalable bioprocess for manufacturing human red blood cells derived from induced pluripotent stem cells (iPSCs), with specific applications in creating designer RBCs for antibody identification in patients requiring blood transfusions. SAFI has collaborated with research partners like The Geneva Foundation on sub-awards involving cell sourcing, bioprocessing optimization, downstream expansion, and scale-up piloting. The grant work encompasses comprehensive research activities including pre-clinical in vitro and in vivo studies, regulatory planning, and commercialization strategies for blood cell manufacturing reagents. These federal grants demonstrate SAFI's commitment to innovative bioprocessing technologies that can potentially improve blood transfusion diagnostics and therapeutics, particularly for patients with complex blood disorders like sickle cell disease.
Quick answers
What is SAFI Biotherapeutics Inc.'s UEI?
SAFI Biotherapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is LQ1FYSTC9L65.
What is SAFI Biotherapeutics Inc.'s CAGE code?
SAFI Biotherapeutics Inc.'s CAGE code is 8JC22.
What is SAFI Biotherapeutics Inc.'s primary NAICS code?
SAFI Biotherapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is SAFI Biotherapeutics Inc. located?
SAFI Biotherapeutics Inc.'s physical address in SAM.gov is 1 Broadway, Cambridge, MA 02142, USA.
Is SAFI Biotherapeutics Inc. registered in SAM.gov?
Yes. SAFI Biotherapeutics Inc.'s SAM.gov registration is active through January 31, 2027.
What is SAFI Biotherapeutics Inc.'s most recent federal award?
SAFI Biotherapeutics Inc.'s most recent federal grant award is Manufacturing process intensification for pluripotent stem cell-derived rare red cell production - project… (R41HL178144), from National Heart Lung and Blood Institute, on April 1, 2025.
On GovTribe
See SAFI Biotherapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors